These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33798648)

  • 1. Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases.
    Tallon C; Hollinger KR; Pal A; Bell BJ; Rais R; Tsukamoto T; Witwer KW; Haughey NJ; Slusher BS
    Drug Discov Today; 2021 Jul; 26(7):1656-1668. PubMed ID: 33798648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury.
    Tallon C; Picciolini S; Yoo SW; Thomas AG; Pal A; Alt J; Carlomagno C; Gualerzi A; Rais R; Haughey NJ; Bedoni M; Slusher BS
    Biochem Pharmacol; 2021 Dec; 194():114796. PubMed ID: 34678224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Neutral Sphingomyelinase 2 by Novel Small Molecule Inhibitors Results in Decreased Release of Extracellular Vesicles by Vascular Smooth Muscle Cells and Attenuated Calcification.
    Pavlic A; Poelman H; Wasilewski G; Wichapong K; Lux P; Maassen C; Lutgens E; Schurgers LJ; Reutelingsperger CP; Nicolaes GAF
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceramide-mediated orchestration of oxidative stress response through filopodia-derived small extracellular vesicles.
    Quadri Z; Elsherbini A; Crivelli SM; El-Amouri SS; Tripathi P; Zhu Z; Ren X; Zhang L; Spassieva SD; Nikolova-Karakashian M; Bieberich E
    J Extracell Vesicles; 2024 Jul; 13(7):e12477. PubMed ID: 38988257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proinflammatory stress activates neutral sphingomyelinase 2 based generation of a ceramide-enriched β cell EV subpopulation.
    Xu J; Harris-Kawano A; Enriquez JR; Mirmira RG; Sims EK
    bioRxiv; 2024 Apr; ():. PubMed ID: 38659945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties.
    Figuera-Losada M; Stathis M; Dorskind JM; Thomas AG; Bandaru VV; Yoo SW; Westwood NJ; Rogers GW; McArthur JC; Haughey NJ; Slusher BS; Rojas C
    PLoS One; 2015; 10(5):e0124481. PubMed ID: 26010541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of nSMase2 Reduces the Transfer of Oligomeric α-Synuclein Irrespective of Hypoxia.
    Sackmann V; Sinha MS; Sackmann C; Civitelli L; Bergström J; Ansell-Schultz A; Hallbeck M
    Front Mol Neurosci; 2019; 12():200. PubMed ID: 31555088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutral sphingomyelinase 2 inhibition attenuates extracellular vesicle release and improves neurobehavioral deficits in murine HIV.
    Zhu X; Hollinger KR; Huang Y; Borjabad A; Kim BH; Arab T; Thomas AG; Moniruzzaman M; Lovell L; Turchinovich A; Witwer KW; Volsky DJ; Haughey NJ; Slusher BS
    Neurobiol Dis; 2022 Jul; 169():105734. PubMed ID: 35462006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of neutral sphingomyelinase 2 through hyperglycemia contributes to endothelial apoptosis via vesicle-bound intercellular transfer of ceramides.
    Zietzer A; Jahnel AL; Bulic M; Gutbrod K; Düsing P; Hosen MR; Dörmann P; Werner N; Nickenig G; Jansen F
    Cell Mol Life Sci; 2021 Dec; 79(1):48. PubMed ID: 34951654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neutral sphingomyelinase pathway regulates packaging of the prion protein into exosomes.
    Guo BB; Bellingham SA; Hill AF
    J Biol Chem; 2015 Feb; 290(6):3455-67. PubMed ID: 25505180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA Damage Regulates Senescence-Associated Extracellular Vesicle Release via the Ceramide Pathway to Prevent Excessive Inflammatory Responses.
    Hitomi K; Okada R; Loo TM; Miyata K; Nakamura AJ; Takahashi A
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson's disease model.
    Zhu C; Bilousova T; Focht S; Jun M; Elias CJ; Melnik M; Chandra S; Campagna J; Cohn W; Hatami A; Spilman P; Gylys KH; John V
    Mol Brain; 2021 Apr; 14(1):70. PubMed ID: 33875010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in murine Alzheimer's disease.
    Tallon C; Bell BJ; Malvankar MM; Deme P; Nogueras-Ortiz C; Eren E; Thomas AG; Hollinger KR; Pal A; Mustapic M; Huang M; Coleman K; Joe TR; Rais R; Haughey NJ; Kapogiannis D; Slusher BS
    Res Sq; 2023 Jul; ():. PubMed ID: 37502930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer's disease mouse model.
    Tallon C; Bell BJ; Malvankar MM; Deme P; Nogueras-Ortiz C; Eren E; Thomas AG; Hollinger KR; Pal A; Mustapic M; Huang M; Coleman K; Joe TR; Rais R; Haughey NJ; Kapogiannis D; Slusher BS
    Transl Neurodegener; 2023 Dec; 12(1):56. PubMed ID: 38049923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of Synaptosomal-Associated Protein 25 with Neutral Sphingomyelinase 2: Functional Impact on the Sphingomyelin Pathway.
    Won JH; Jeon HJ; Kim SK; Shin IC; Jang JM; Ha HC; Back MJ; Kim DK
    Neuroscience; 2020 Feb; 427():1-15. PubMed ID: 31765623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. nSMase2 (Type 2-Neutral Sphingomyelinase) Deficiency or Inhibition by GW4869 Reduces Inflammation and Atherosclerosis in Apoe
    Lallemand T; Rouahi M; Swiader A; Grazide MH; Geoffre N; Alayrac P; Recazens E; Coste A; Salvayre R; Nègre-Salvayre A; Augé N
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1479-1492. PubMed ID: 29794115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of tau propagation using an inhibitor that targets the DK-switch of nSMase2.
    Bilousova T; Elias C; Miyoshi E; Alam MP; Zhu C; Campagna J; Vadivel K; Jagodzinska B; Gylys KH; John V
    Biochem Biophys Res Commun; 2018 May; 499(4):751-757. PubMed ID: 29604274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulated translocation of neutral sphingomyelinase-2 to the plasma membrane drives insulin resistance in steatotic hepatocytes.
    El-Amouri S; Karakashian A; Bieberich E; Nikolova-Karakashian M
    J Lipid Res; 2023 Oct; 64(10):100435. PubMed ID: 37640282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Human Neutral Sphingomyelinase 2 Inhibitors as Potential Therapeutics for Alzheimer's Disease.
    Šála M; Hollinger KR; Thomas AG; Dash RP; Tallon C; Veeravalli V; Lovell L; Kögler M; Hřebabecký H; Procházková E; Nešuta O; Donoghue A; Lam J; Rais R; Rojas C; Slusher BS; Nencka R
    J Med Chem; 2020 Jun; 63(11):6028-6056. PubMed ID: 32298582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutral sphingomyelinase 2 controls exosome secretion by counteracting V-ATPase-mediated endosome acidification.
    Choezom D; Gross JC
    J Cell Sci; 2022 Mar; 135(5):. PubMed ID: 35050379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.